Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Maarten E.A. Reith

2 papers in the library · 49 citations · publishing 2012-2013

Papers

Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

PLoS One January 1, 2013 Tamara Antonio, Steven R Childers, Richard B Rothman et al. 36 citations

Iboga alkaloids, including ibogaine, its metabolite noribogaine, and the synthetic compound 18-methoxycoronaridine (18-MC), were tested for their ability to activate the μ-opioid receptor (MOR), a common target of opioid drugs. In rat thalamic membranes, all three compounds acted as antagonists, blocking the receptor rather than activating it, with functional Ke values ranging from 3 μM for ibogaine to 13 μM for noribogaine and 18-MC. None of the compounds stimulated MOR-related G protein activity in cells expressing human or rat MORs, and only limited partial agonist effects were seen in mouse MOR-expressing cells. The findings indicate that an opioid agonist mechanism does not explain these alkaloids' effects on opioid withdrawal, supporting a novel mechanism of action and justifying further search for alternative targets.

Ibogaine and the inhibition of acetylcholinesterase.

Journal of Ethnopharmacology February 15, 2012 Kenneth Alper, Maarten E.A. Reith, Henry Sershen 13 citations

Ibogaine, a psychoactive alkaloid from the root bark of Tabernanthe iboga, is used to treat addiction and is a candidate for pharmaceutical development. Its ability to inhibit acetylcholinesterase (AChE) has pharmacological and toxicological relevance. Using Ellman's reagent with physostigmine as a control, ibogaine inhibited AChE with an IC50 of 520 ± 40 μM. This inhibition is physiologically negligible and does not explain functional effects in animals or humans that might suggest involvement of muscarinic acetylcholine pathways.